PsyBio Therapeutics Corp. (PSYBF)
| Previous Close | 0.0754 |
| Open | 0.0800 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.0800 - 0.0970 |
| 52 Week Range | 0.0373 - 0.6100 |
| Volume | |
| Avg. Volume | 43,564 |
| Market Cap | 11.071M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0860 |
| Earnings Date | Jun 01, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- CNW Group
PsyBio Therapeutics Initiates Commercial Biosynthetic Based Process Development for Psycho-Targeted and Psychoactive Compounds
PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) ("PsyBio" or the "Company"), a fully integrated and intellectual property driven biotechnology company developing novel, bespoke psychoactive medicinal candidates targeting the potential treatment of mental health challenges, neurological disorders and other human health conditions, today reported that it has initiated formal process development for commercially scalable, patent pending manufacturing technology expected to enable Good Manufac
- CNW Group
PsyBio Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update on Intellectual Property and Clinical Development Milestones
PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) ("PsyBio" or the "Company"), a fully integrated and intellectual property driven biotechnology company developing novel, bespoke psychoactive medicinal candidates targeting the potential treatment of mental health challenges, neurological disorders and other human health conditions, today announced that it has reported its interim financial results for the three month period ended March 31, 2022 and provided shareholders with a corporate upda
- CNW Group
PsyBio Therapeutics Develops Commercial Purification Process for Second Generation Psycho-Targeted Compound
PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) ("PsyBio" or the "Company"), a fully integrated and intellectual property driven biotechnology company developing novel, bespoke psychoactive medicinal candidates targeting the potential treatment of mental health challenges, neurological disorders and other human health conditions, today reported that it has achieved a commercially scalable purification method for one of its second generation compounds. This manufacturing process achievement
